{"prompt": "['056-F275, Clinical Investigation Plan Template, Version 2.0', 'Page 1 of 115', 'Medtronic', 'Clinical Investigation Plan', 'Clinical Investigation Plan/Study Title', 'STOP Persistent AF', 'Study Product Name', 'Arctic Front AdvanceTM Cardiac CryoAblation Catheter', 'Freezor MAX\u00ae Cardiac CryoAblation Catheter', 'United States of America', 'Sponsor/Local Sponsor', 'Medtronic, Inc.', '8200 Coral Sea Street NE', 'Mounds View, MN 55112', 'United States of America', 'Canada', 'Medtronic of Canada, Ltd.', '99 Hereford Street', 'Brampton, Ontario, L6Y OR3', 'Canada', 'Europe', 'Medtronic, Bakken Research Center B.V.', 'Endeplosdomein 5', '6229 GW Maastricht', 'The Netherlands', 'Japan', 'Medtronic Japan Co. Ltd.', '1-2-70 Konan', 'Minato-ku, Tokyo 108-0075', 'Japan', 'Document Version', '4, 10NOV2016', 'Hugh Calkins, MD', 'Lead Co-Principal', 'Address: Johns Hopkins, 1800 Orleans Street, Zayed', 'nvestigator(s)/Coordinating Investigators', 'Tower 712R, Baltimore, MD 21287', 'Telephone: 410-955-7405', 'Fax: 410-614-1345', 'Professional Position: Nicholas J. Fortuin Professor of', 'Cardiology, Division of Cardiology, The Johns Hopkins', 'University School of Medicine. Professor of Medicine,', 'Department of Medicine, Division of Cardiology, The', 'Johns Hopkins University School of Medicine. Professor', 'of Pediatrics, Department of Pediatrics, Division of', 'Pediatric Cardiology, The Johns Hopkins University', 'School of Medicine. Director of the Arrhythmia Service,', 'Version 4, 10NOV2016', 'Confidential']['056-F275, Clinical Investigation Plan Template, Version 2.0', 'Page 2 of 115', 'Clinical Electrophysiology Laboratory, and', 'Arrhythmogenic Right Ventricular Dysplasia Program,', 'The Johns Hopkins Hospital', 'Vivek Reddy, MD', 'Address: Mt. Sinai Heart, One Gustave L Levy Place, Box', '1030, New York, NY 10029', 'Telephone: 212-241-7114', 'Fax: 646-537-9691', 'Professional Position: The Leona M. and Harry B.', 'Helmsley Charitable Trust Professor of Medicine in', 'Cardiac Electrophysiology', 'Robert Kowal, MD', 'Coordinating Investigators', 'Address: Cardiology Consultants of Texas, 621 North', 'Hall Street, Suite 4400, Dallas, TX 75226', 'Telephone: 469-800-7400', 'Fax: 469-800-7410', 'Professional Position: Co-Medical Director, Cardiac', 'Electrophysiology', 'Baylor Scott and White Health Care', 'VP and Medical Director, Best Care and Clinical', 'Integration', 'Baylor Scott and White Quality Alliance', 'Wilbur Su, MD', 'Address: Banner-University Medical Group-Heart Center', '1300 North 12th Street, Suite 407, Phoenix, AZ 58006', 'Telephone: 602-839-7393', 'Professional Position: Clinical Assoc. Professor of', 'Medicine, University of Arizona, Chief of Cardiac EP,', 'Lanner-University Medical Center-Phoenix, Director of', 'EP Fellowship, Banner-University Medical Center-', 'Phoenix', 'Confidentiality Statement', 'The information contained in this document is confidential and the proprietary property of Medtronic. Any', 'distribution, copying, or disclosure without the prior written authorization of Medtronic is strictly prohibited.', 'Persons to whom the information is disclosed must know that it is confidential and that it may not be further', 'disclosed by them.', 'Version 4, 10NOVO016', 'Confidential']['056-F275, Clinical Investigation Plan Template, Version 2.0', 'Page 3 of 115', '1. Version History', 'Version', 'Summary of Changes', 'Rationale', 'Author(s)/Title', '1.0', 'Not Applicable, New', 'Not Applicable, New Document', 'Dana Wigert, Sr. Prin. Clinical', 'Document', 'Research Specialist', 'Fred Kueffer, Pr. Statistician', '2.0', 'Synopsis, Sections 7.1, 7.2', 'FDA feedback', 'Dana Wigert, Sr. Prin. Clinical', 'and 18: Modified the', 'Research Specialist', 'primary efficacy OPC and', 'Fred Kueffer, Pr. Statistician', 'changed the atypical', 'flutter treatment failure to', 'any recurrence of atrial', 'flutter', '2.0', 'Synopsis, Sections 7.1, 7.2', 'FDA feedback', 'Dana Wigert, Sr. Prin. Clinical', '14.16 and 18.3.2: Changed', 'Research Specialist', 'the secondary safety', 'Fred Kueffer, Pr. Statistician', 'objective to a primary', 'safety objective with a', 'pre-specified hypothesis', '2.0', 'Synopsis, Sections 7.1, 7.2', 'Dana Wigert, Sr. Prin. Clinical', 'and 18.5: Added an', 'Research Specialist', 'ancillary objective', 'Fred Kueffer, Pr. Statistician', '2.0', 'Synopsis, Sections 7.1, 7.2', 'Dana Wigert, Sr. Prin. Clinical', 'and 18.5: Added and', 'Research Specialist', 'ancillary objective', 'Fred Kueffer, Pr. Statistician', '2.0', 'Synopsis, Sections 7.1, 7.2', 'Dana Wigert, Sr. Prin. Clinical', 'and 18.5: Removed', 'Research Specialist', 'Fred Kueffer, Pr. Statistician', 'ancillary', 'objective', '2.0', 'Synopsis, Sections 5, 8', 'Participation and enrollment in', 'Dana Wigert, Sr. Prin. Clinical', 'and 18: Study data from', 'Japan is anticipated to start', 'Research Specialist', 'the Japanese centers will', 'later than the other', 'Fred Kueffer, Pr. Statistician', 'not be included in the', 'geographies', 'PMA-S submission, but will', 'Version 4, 10NOVO016', 'Confidential']\n\n###\n\n", "completion": "END"}